Company intelligence
Drug Hunter
the science of drug discovery, distilled for innovators. discover more at drughunter.com
About Drug Hunter
Drug Hunter™ is reinventing drug discovery intelligence for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry lessons from thousands of sources into a one-of-a-kind searchable platform for drug discovery knowledge you can apply to make better decisions and solve critical discovery challenges. Founded and run by a team of industry scientists, Drug Hunter now serves >200 innovative institutions worldwide including top pharma and biotech companies, investors, and non-profits.
Verified activity
Signals from Drug Hunter
9 published signals
Research & Knowledge
Drug Hunter published an article and accompanying poster covering eight small molecules from EFMC Medicinal Chemistry 2026 first time disclosure sessions, including AZD4248, NVP-ITU512, UCB6492, BI 706321, RG6182, zilurgisertib, and Clasornoflast.
Reported by Drug Hunter
Research & Knowledge
Drug Hunter featured Angela Russell, Professor of Medicinal Chemistry at the University of Oxford, presenting the clinical development and discovery of ezutromid, a first-in-class small-molecule utrophin modulator identified through phenotypic screening.
Reported by Drug Hunter
Research & Knowledge
Drug Hunter reported that the pivotal JACKPOT8 Part B study reported an IRC-assessed ORR of 44%, CR rate of 24%, and median DOR of 21 months supporting the conditional approval of Golidocitinib in China in 2024.
Reported by Drug Hunter
Presence & Recognition
Drug Hunter is heading to Basel, Switzerland for the EFMC European Federation for Medicinal Chemistry and Chemical Biology International Symposium on Medicinal Chemistry from September 6-10.
Reported by Drug Hunter
Legal & Regulatory
Drug Hunter reported that Iberdomide, a CRBN-mediated molecular glue degrader of IKZF1 and IKZF3, received accelerated FDA approval for the treatment of multiple myeloma in August 2026.
Reported by Drug Hunter
Research & Knowledge
Drug Hunter published recent Ph. 2b ACCESS data showing that Structure Therapeutics' aleniglipron entered a clinically meaningful weight loss phase with no apparent plateau at week 36 and continued weight reductions in the open-label extension.
Reported by Drug Hunter
Presence & Recognition
Drug Hunter featured Dean Brown, Senior Vice President and Head of Discovery Sciences at Jnana Therapeutics presenting an analysis of 104 oral small molecule drugs approved by the FDA between 2020 and 2024.
Reported by Drug Hunter
Research & Knowledge
Drug Hunter spotlighted July 2026 molecules including ARTIOS PHARMA LIMITED’s ART6043, Eli Lilly and Company’s LY3410738, and Roche’s nivegacetor.
Reported by Drug Hunter
People
Drug Hunter is hiring a Director of Sales to join the team.
Reported by Sarah St. John